Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)‘s stock had its “buy” rating reiterated by analysts at Wedbush in a research note issued to investors on Friday. They presently have a $33.00 target price on the stock. Wedbush’s target price would indicate a potential upside of 189.98% from the company’s current price.

Separately, Zacks Investment Research upgraded shares of Verona Pharma PLC American Depositary Share from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.20.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) traded down $0.20 during trading on Friday, hitting $11.38. 9,800 shares of the stock traded hands, compared to its average volume of 5,671. Verona Pharma PLC American Depositary Share has a 1 year low of $10.44 and a 1 year high of $17.50.

A number of hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC purchased a new stake in Verona Pharma PLC American Depositary Share in the second quarter worth $8,208,000. Tekla Capital Management LLC purchased a new stake in Verona Pharma PLC American Depositary Share in the second quarter worth $3,211,000. Finally, FIL Ltd purchased a new stake in Verona Pharma PLC American Depositary Share in the second quarter worth $873,000. 40.27% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/08/verona-pharma-plc-american-depositary-share-vrna-stock-rating-reaffirmed-by-wedbush.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.